SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy
David K Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J Clark, Nicholas Eckersley, Henry M Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao, David K Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J Clark, Nicholas Eckersley, Henry M Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao
Abstract
Introduction: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination.
Materials and methods: Between September 2020 and April 2021, patients with cancer undergoing chemotherapy were enrolled. At baseline (day 0), days 28, 56, and 84, we assessed serum antibodies to SARS-CoV-2 spike (anti-S) and anti-nucleocapsid (anti-NP) and concomitantly assessed virus neutralization using a pseudovirus neutralization assay. Patients received either the Pfizer/BioNTech BNT162b2, or the Oxford/AstraZeneca ChAdOx1 vaccine.
Results: All 152 patients enrolled had a prior diagnosis of cancer; colorectal (n = 80, 52.6%), oesophagogastric (n = 38, 25.0%), and hepato pancreatic biliary (n = 22, 12.5%). Nearly all were receiving systemic anti-cancer therapy (99.3%). Of the 51 patients who did not receive a vaccination prior to, or during the study, 5 patients had detectable anti-NP antibodies. Ninety-nine patients received at least one dose of vaccine prior to, or during the study. Within 19 days following the first dose of vaccine, 30.0% had anti-S detected in serum which increased to 70.2% at days 20-39. In the 19 days following a second dose, anti-S positivity was 84.2% (32/38). However, pseudovirus neutralization titers (pVNT80) decreased from days 20 to 39.
Conclusion: Despite the immunosuppressive effects of chemotherapy, 2 doses of SARS-CoV-2 vaccines are able to elicit a protective immune response in patients' ongoing treatment for gastrointestinal cancers. Decreases in pseudoviral neutralization were observed after 20-39 days, re-affirming the current recommendation for vaccine booster doses.
Clinical trial registration number: NCT04427280.
Keywords: COVID-19; SARS-CoV-2; anti-spike; chemotherapy; gastrointestinal cancer; immunity; pseudovirus; vaccines.
© The Author(s) 2022. Published by Oxford University Press.
Figures
References
- WHO Coronavirus (COVID-19) Dashboard. Accessed March 3, 2022.
- Liang W, Guan W, Chen R, et al. . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. 10.1016/S1470-2045(20)30096-6.
- Yu J, Ouyang W, Chua MLK, Xie C.. SARS-CoV-2 Transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108-1110. 10.1001/jamaoncol.2020.0980.
- Voysey M, Clemens SAC, Madhi SA, et al. . Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397(10269):99-111. 10.1016/S0140-6736(20)32661-1.
- Polack FP, Thomas SJ, Kitchin N, et al. . C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. 10.1056/nejmoa2034577.
- Department of Health and Social Care. Prioritising the first COVID-19 vaccine dose: JCVI statement . Accessed March 3, 2022.
- Sung H, Ferlay J, Siegel RL, et al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 Countries. CA. 2021;71(3):209-249. 10.3322/caac.21660.
- Addeo A, Shah PK, Bordry N, et al. . Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091-1098.e2. 10.1016/j.ccell.2021.06.009.
- Goshen-Lago T, Waldhorn I, Holland R, et al. . Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507-1513. 10.1001/jamaoncol.2021.2675.
- Massarweh A, Eliakim-Raz N, Stemmer A, et al. . Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133-1140. 10.1001/jamaoncol.2021.2155.
- Di Genova C, Sampson A, Scott S, et al. . Production, titration, neutralisation, storage and lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) lentiviral pseudotypes. Bio-protocol. 2021;11(21):e4236. 10.21769/BioProtoc.4236.
- Hyseni I, Molesti E, Benincasa L, et al. . Characterisation of SARS-CoV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays. Viruses. 2020;12(9):1011. 10.3390/v12091011.
- Thompson CP, Grayson NE, Paton RS, et al. . Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveillance: Bull Eur sur les Maladies Transmiss = Eur Commun Dis Bull. 2020;25(42):2000685. 10.2807/1560-7917.es.2020.25.42.2000685.
- Hall V, Foulkes S, Insalata F, et al. . Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207-1220. 10.1056/NEJMoa2118691.
- Wei J, Pouwels KB, Stoesser N, et al. . Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28(5):1072-1082. 10.1038/s41591-022-01721-6.
- Monin L, Laing AG, Muñoz-Ruiz M, et al. . Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765-778. 10.1016/S1470-2045(21)00213-8.
- Tran S, Truong TH, Narendran A.. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer (Oxford, England: 1990). 2021;159:259-274. 10.1016/j.ejca.2021.10.013.
- Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. . Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e2. 10.1016/j.ccell.2021.06.002.
- Naranbhai V, Pernat CA, Gavralidis A, et al. . Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX Cohort Study. J Clin Oncol. 2022;40(1):12-23. 10.1200/jco.21.01891.
- Greenberger LM, Saltzman LA, Senefeld JW, et al. . Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031-1033. 10.1016/j.ccell.2021.07.012.
- Bird S, Panopoulou A, Shea RL, et al. . Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8(6):e389-e392. 10.1016/S2352-3026(21)00110-1.
- Agha M, Blake M, Chilleo C, Wells A, Haidar G.. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv: The Preprint Server Health Sci. 2021: 2021.04.06.21254949. 10.1101/2021.04.06.21254949.
- Herishanu Y, Avivi I, Aharon A, et al. . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-3173. 10.1182/blood.2021011568.
- Chang A, Akhtar A, Linderman SL, et al. . Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-hodgkin lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 2022;40(26):3020-3031. 10.1200/jco.22.00088.
- Savage HR, Santos VS, Edwards T, et al. . Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis. PLoS NeglTrop Dis. 2021;15(7):e0009551. 10.1371/journal.pntd.0009551.
- Infantino M, Pieri M, Nuccetelli M, et al. . The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol. 2021;100:108095-108095. 10.1016/j.intimp.2021.108095.
- Knezevic I, Mattiuzzo G, Page M, et al. . WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2022;3(3):e235-e240. 10.1016/S2666-5247(21)00266-4.
- Barrière J, Chamorey E, Adjtoutah Z, et al. . Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053-1055. 10.1016/j.annonc.2021.04.019.
- Garcia-Beltran WF, Lam EC, St Denis K, et al. . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372-2383.e9. 10.1016/j.cell.2021.03.013.
- Dejnirattisai W, Huo J, Zhou D, et al. ; OPTIC Consortium. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467-484.e15. 10.1016/j.cell.2021.12.046.
- Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. . mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457-466.e4. 10.1016/j.cell.2021.12.033.
- Earle KA, Ambrosino DM, Fiore-Gartland A, et al. . Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428. 10.1016/j.vaccine.2021.05.063.
Source: PubMed